OncoMatch/Clinical Trials/NCT05425004
Cabozantinib for Patients With Recurrent or Progressive Meningioma
Is NCT05425004 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Cabozantinib for meningioma.
Treatment: Cabozantinib — A Phase II Study of Cabozantinib for Patients with Recurrent or Progressive Meningioma
Check if I qualifyExtracted eligibility criteria
Treatments studied
Targeted therapy
Disease stage
Required: Stage I, II, III (WHO)
All World Health Organization (WHO) grades (I, II and III) are allowed. Patients must have measurable disease by iRANO criteria
Prior therapy
Must have received: standard therapy (radiation, surgery)
All patients must have developed recurrent disease or progressive disease after receiving standard therapy (e.g., radiation or surgery) > 6 months ago or have been deemed ineligible to receive these therapies.
Cannot have received: cabozantinib (cabozantinib)
Prior treatment with cabozantinib.
Lab requirements
Blood counts
Absolute Neutrophil Count ≥ 1.5 x 10^9 / L without G-CSF support; Platelet Count ≥ 100 x 10^9 / L without transfusion; Hemoglobin ≥ 9 g/dL without transfusion within 7 days prior to screening assessment.
Kidney function
≥ 30 ml/min according to the Cockcroft-Gault formula.
Liver function
Total bilirubin ≤ 1.5 x ULN; AST ≤ 3 x ULN without liver metastasis; ALT ≤ 3 x ULN without liver metastasis; AST or ALT ≤ 5 x ULN for patients with liver metastasis; Gilbert's syndrome allowed if total bilirubin ≤ 3 x ULN.
Cardiac function
Ejection fraction (EF) > 50% by ECHO or MUGA if ECHO insufficient; QTcF ≤ 500 ms within 14 days of study registration (if initial QTcF >500 ms, average of two additional EKGs ≤ 500 ms required); Prothrombin time (PT)/INR or PTT < 1.3x ULN.
Adequate hematologic function: ANC ≥ 1.5 x 10^9 / L without G-CSF support; Platelet Count ≥ 100 x 10^9 / L without transfusion; Hemoglobin ≥ 9 g/dL without transfusion within 7 days prior to screening assessment. Adequate renal function: ≥ 30 ml/min according to the Cockcroft-Gault formula. Adequate hepatic function including: Total bilirubin ≤ 1.5 x ULN; AST ≤ 3 x ULN without liver metastasis; ALT ≤ 3 x ULN without liver metastasis; AST or ALT ≤ 5 x ULN for patients with liver metastasis; Gilbert's syndrome allowed if total bilirubin ≤ 3 x ULN. Serum albumin ≥ 2.8 g/dL. PT/INR or PTT < 1.3x ULN. Ejection fraction (EF) > 50% by ECHO or MUGA if ECHO insufficient. QTcF ≤ 500 ms within 14 days of study registration (if initial QTcF >500 ms, average of two additional EKGs ≤ 500 ms required).
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Miami Cancer Institute at Baptist Health, Inc. · Miami, Florida
- Memorial Sloan Kettering Cancer Center · New York, New York
- Vanderbilt University Medical Center · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT05425004 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior cabozantinib disqualifies patients from enrollment.
What disease stage is eligible?
Stage I or II or III is required.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify